Official Title
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia
Brief Summary

The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities

Withdrawn
Patients With COVID19

Drug: Hydroxychloroquine

400mg per day during 10 days

Drug: Azithromycin

500 mg per day during 5 days

Eligibility Criteria

Inclusion Criteria:

- confirmed COVID19 (+)

- Qt<500ms

- no severity criteria

- pauci-symptomatique patients

- signed consent form

Exclusion Criteria:

- no confirmed patient COVID19

- severity criteria

- known allegies to macrolides and HCQ

- Treated with HCQ within 1 month prior to inclusion

- hepatitis insufficiency

- Renal insufficiency

- treatment no indicated with azithro and HCQ

- hypovolemia

- complete brach block

- retinopathia

- psoriasis

- pregnancy or breastfeeding

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 80 Years
Countries
Tunisia
Locations

Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana
Tunis, Tunisia

Abderrahmane Mami Hospital
NCT Number
MeSH Terms
COVID-19
Azithromycin
Hydroxychloroquine